Symbols / ANIX
ANIX Chart
About
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 100.14M |
| Enterprise Value | 83.95M | Income | -10.93M | Sales | — |
| Book/sh | 0.46 | Cash/sh | 0.46 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -8.11 | PEG | — |
| P/S | — | P/B | 6.54 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 7.71 |
| Current Ratio | 8.08 | Debt/Eq | 1.46 | LT Debt/Eq | — |
| EPS (ttm) | -0.34 | EPS next Y | -0.37 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-09 | ROA | -38.83% |
| ROE | -67.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 33.38M |
| Shs Float | 31.57M | Short Float | 3.76% | Short Ratio | 5.19 |
| Short Interest | — | 52W High | 5.46 | 52W Low | 2.33 |
| Beta | 0.49 | Avg Volume | 313.01K | Volume | 154.89K |
| Target Price | $10.75 | Recom | None | Prev Close | $2.93 |
| Price | $3.00 | Change | 2.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.75
Mean price target
2. Current target
$3.00
Latest analyst target
3. DCF / Fair value
$-1.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.00
Low
$9.00
High
$14.00
Mean
$10.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-04 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-12-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-10-07 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-09-09 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-19 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-05 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-10 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-10 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-26 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-21 | init | Maxim Group | — → Buy | $10 |
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-22 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-01-14 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-19 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-11 | main | D. Boral Capital | Buy → Buy | $10 |
- Co-inventor of Anixa cancer CAR-T to headline 2026 cell therapy retreat - Stock Titan Mon, 23 Feb 2026 13
- Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Analysts - MarketBeat ue, 24 Feb 2026 10
- Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Wed, 05 Nov 2025 08
- $ANIX stock is down 23% today. Here's what we see in our data. - Quiver Quantitative Fri, 12 Dec 2025 08
- D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq ue, 07 Oct 2025 07
- Experimental ovarian cancer CAR-T earns official U.S. drug name - Stock Titan Mon, 02 Feb 2026 08
- Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year? - Yahoo Finance Wed, 09 Jul 2025 07
- $ANIX stock is up 19% today. Here's what we see in our data. - Quiver Quantitative ue, 07 Oct 2025 07
- ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy? - Nasdaq hu, 26 Jun 2025 07
- Anixa Biosciences (NASDAQ:ANIX) Lowered to Sell Rating by Wall Street Zen - MarketBeat Sat, 07 Feb 2026 08
- Anixa Biosciences (NASDAQ: ANIX) Phase 1 breast cancer vaccine data met endpoints with 74% immune response - Stock Titan hu, 11 Dec 2025 08
- $ANIX stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 15 Sep 2025 07
- D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq Fri, 12 Dec 2025 08
- Anixa Biosciences (NASDAQ:ANIX) Director Arnold Baskies Acquires 10,000 Shares - MarketBeat hu, 29 Jan 2026 08
- Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation - Yahoo Finance Sun, 08 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | 30400 | — | Purchase at price 3.04 per share. | BASKIES ARNOLD M | Director | — | 2026-01-28 00:00:00 | D |
| 1 | 16000 | 46720 | — | Conversion of Exercise of derivative security at price 2.92 per share. | TITTERTON LEWIS H JR | Director | — | 2025-12-15 00:00:00 | D |
| 2 | 200000 | 584000 | — | Conversion of Exercise of derivative security at price 2.92 per share. | KUMAR AMIT | Chief Executive Officer | — | 2025-10-30 00:00:00 | D |
| 3 | 10000 | 30800 | — | Purchase at price 3.08 per share. | TITTERTON LEWIS H JR | Director | — | 2025-07-31 00:00:00 | D |
| 4 | 5000 | 15800 | — | Purchase at price 3.16 per share. | KUMAR AMIT | Chief Executive Officer | — | 2025-07-30 00:00:00 | D |
| 5 | 5000 | 16950 | — | Purchase at price 3.39 per share. | BASKIES ARNOLD M | Director | — | 2025-07-18 00:00:00 | D |
| 6 | 5000 | 15750 | — | Purchase at price 3.15 per share. | KUMAR AMIT | Chief Executive Officer | — | 2025-07-11 00:00:00 | D |
| 7 | 10000 | 31400 | — | Purchase at price 3.14 per share. | TITTERTON LEWIS H JR | Director | — | 2025-07-11 00:00:00 | D |
| 8 | 10000 | 28500 | — | Purchase at price 2.85 per share. | KUMAR AMIT | Chief Executive Officer | — | 2025-06-04 00:00:00 | D |
| 9 | 5000 | 14100 | — | Purchase at price 2.82 per share. | BASKIES ARNOLD M | Director | — | 2025-01-28 00:00:00 | D |
Financials
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.66M | -13.79M | -10.96M | -13.83M |
| TotalUnusualItems | 0.00 | 6.00K | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 6.00K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.93M | -12.55M | -9.81M | -13.60M |
| ReconciledDepreciation | 36.00K | 37.00K | 46.00K | 42.00K |
| ReconciledCostOfRevenue | 0.00 | 161.00K | 0.00 | 385.00K |
| EBITDA | -11.66M | -13.79M | -10.96M | -13.83M |
| EBIT | -11.70M | -13.83M | -11.01M | -13.88M |
| NetInterestIncome | 673.00K | 1.13M | 1.08M | 104.00K |
| InterestIncome | 673.00K | 1.13M | 1.08M | 104.00K |
| NormalizedIncome | -10.93M | -12.55M | -9.81M | -13.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.93M | -12.55M | -9.81M | -13.60M |
| TotalExpenses | 11.70M | 13.83M | 11.22M | 13.88M |
| TotalOperatingIncomeAsReported | -11.70M | -13.83M | -11.01M | -13.88M |
| DilutedAverageShares | 32.45M | 31.90M | 30.98M | 30.37M |
| BasicAverageShares | 32.45M | 31.90M | 30.98M | 30.37M |
| DilutedEPS | -0.34 | -0.39 | -0.32 | -0.45 |
| BasicEPS | -0.34 | -0.39 | -0.32 | -0.45 |
| DilutedNIAvailtoComStockholders | -10.93M | -12.55M | -9.81M | -13.60M |
| NetIncomeCommonStockholders | -10.93M | -12.55M | -9.81M | -13.60M |
| NetIncome | -10.93M | -12.55M | -9.81M | -13.60M |
| MinorityInterests | 101.00K | 144.00K | 119.00K | 176.00K |
| NetIncomeIncludingNoncontrollingInterests | -11.03M | -12.70M | -9.93M | -13.77M |
| NetIncomeContinuousOperations | -11.03M | -12.70M | -9.93M | -13.77M |
| PretaxIncome | -11.03M | -12.70M | -9.93M | -13.77M |
| OtherIncomeExpense | 6.00K | |||
| SpecialIncomeCharges | 0.00 | 6.00K | ||
| GainOnSaleOfPPE | 0.00 | 6.00K | ||
| NetNonOperatingInterestIncomeExpense | 673.00K | 1.13M | 1.08M | 104.00K |
| InterestIncomeNonOperating | 673.00K | 1.13M | 1.08M | 104.00K |
| OperatingIncome | -11.70M | -13.83M | -11.01M | -13.88M |
| OperatingExpense | 11.70M | 13.83M | 11.06M | 13.88M |
| ResearchAndDevelopment | 5.07M | 6.40M | 4.77M | 6.70M |
| SellingGeneralAndAdministration | 6.63M | 7.43M | 6.29M | 7.17M |
| GeneralAndAdministrativeExpense | 6.63M | 7.43M | 6.29M | 7.17M |
| OtherGandA | 6.63M | 7.43M | 6.29M | 7.17M |
| GrossProfit | 0.00 | 49.00K | 0.00 | 127.00K |
| CostOfRevenue | 0.00 | 161.00K | 0.00 | 385.00K |
| TotalRevenue | 0.00 | 0.00 | 210.00K | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 210.00K | 0.00 |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 33.01M | 32.20M | 31.15M | 30.91M |
| ShareIssued | 33.01M | 32.20M | 31.15M | 30.91M |
| TotalDebt | 204.00K | 232.00K | 175.00K | 221.00K |
| TangibleBookValue | 15.16M | 20.00M | 24.34M | 29.05M |
| InvestedCapital | 15.16M | 20.00M | 24.34M | 29.05M |
| WorkingCapital | 13.92M | 18.86M | 23.33M | 28.16M |
| NetTangibleAssets | 15.16M | 20.00M | 24.34M | 29.05M |
| CapitalLeaseObligations | 204.00K | 232.00K | 175.00K | 221.00K |
| CommonStockEquity | 15.16M | 20.00M | 24.34M | 29.05M |
| TotalCapitalization | 15.16M | 20.00M | 24.34M | 29.05M |
| TotalEquityGrossMinorityInterest | 13.95M | 18.89M | 23.37M | 28.20M |
| MinorityInterest | -1.21M | -1.11M | -966.00K | -847.00K |
| StockholdersEquity | 15.16M | 20.00M | 24.34M | 29.05M |
| TreasuryStock | 0.00 | 6.00K | 0.00 | |
| RetainedEarnings | -251.68M | -240.75M | -228.20M | -218.38M |
| AdditionalPaidInCapital | 266.51M | 260.43M | 252.22M | 247.12M |
| CapitalStock | 330.00K | 322.00K | 311.00K | 309.00K |
| CommonStock | 330.00K | 322.00K | 311.00K | 309.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.13M | 2.70M | 2.15M | 2.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 163.00K | 203.00K | 123.00K | 175.00K |
| LongTermDebtAndCapitalLeaseObligation | 163.00K | 203.00K | 123.00K | 175.00K |
| LongTermCapitalLeaseObligation | 163.00K | 203.00K | 123.00K | 175.00K |
| CurrentLiabilities | 1.97M | 2.50M | 2.03M | 2.04M |
| CurrentDebtAndCapitalLeaseObligation | 41.00K | 29.00K | 52.00K | 46.00K |
| CurrentCapitalLeaseObligation | 41.00K | 29.00K | 52.00K | 46.00K |
| PayablesAndAccruedExpenses | 1.93M | 2.47M | 1.98M | 1.99M |
| CurrentAccruedExpenses | 1.76M | 1.95M | 1.77M | 1.73M |
| Payables | 165.00K | 525.00K | 206.00K | 265.00K |
| AccountsPayable | 165.00K | 525.00K | 206.00K | 265.00K |
| TotalAssets | 16.08M | 21.59M | 25.52M | 30.41M |
| TotalNonCurrentAssets | 193.00K | 229.00K | 166.00K | 212.00K |
| NetPPE | 193.00K | 229.00K | 166.00K | 212.00K |
| GrossPPE | 193.00K | 229.00K | 166.00K | 212.00K |
| Leases | 193.00K | 229.00K | 166.00K | 212.00K |
| BuildingsAndImprovements | 193.00K | 229.00K | 166.00K | 212.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 15.89M | 21.36M | 25.36M | 30.20M |
| OtherCurrentAssets | 713.00K | 1.26M | 1.24M | 467.00K |
| PrepaidAssets | 513.00K | 276.00K | ||
| Receivables | 0.00 | 173.00K | 270.00K | 46.00K |
| AccountsReceivable | 0.00 | 173.00K | 270.00K | 46.00K |
| CashCashEquivalentsAndShortTermInvestments | 15.17M | 19.92M | 23.84M | 29.69M |
| OtherShortTermInvestments | 13.93M | 18.65M | 22.93M | 17.33M |
| CashAndCashEquivalents | 1.24M | 1.27M | 915.00K | 12.36M |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.17M | -7.33M | -6.21M | -6.49M |
| RepurchaseOfCapitalStock | 0.00 | -6.00K | 0.00 | |
| IssuanceOfCapitalStock | 2.38M | 2.96M | 0.00 | 0.00 |
| EndCashPosition | 1.24M | 1.27M | 915.00K | 12.36M |
| BeginningCashPosition | 1.27M | 915.00K | 12.36M | 29.13M |
| ChangesInCash | -27.00K | 356.00K | -11.45M | -16.77M |
| FinancingCashFlow | 2.28M | 3.42M | 366.00K | 452.00K |
| CashFlowFromContinuingFinancingActivities | 2.28M | 3.42M | 366.00K | 452.00K |
| ProceedsFromStockOptionExercised | -98.00K | 466.00K | 366.00K | 452.00K |
| NetCommonStockIssuance | 2.38M | 2.95M | 0.00 | 0.00 |
| CommonStockPayments | 0.00 | -6.00K | 0.00 | |
| CommonStockIssuance | 2.38M | 2.96M | 0.00 | 0.00 |
| InvestingCashFlow | 4.87M | 4.28M | -5.60M | -10.73M |
| CashFlowFromContinuingInvestingActivities | 4.87M | 4.28M | -5.60M | -10.73M |
| NetInvestmentPurchaseAndSale | 4.87M | 4.28M | -5.60M | -10.73M |
| SaleOfInvestment | 49.23M | 68.05M | 38.81M | 11.76M |
| PurchaseOfInvestment | -44.36M | -63.77M | -44.41M | -22.49M |
| NetBusinessPurchaseAndSale | 0.00 | 7.00K | ||
| SaleOfBusiness | 0.00 | 7.00K | ||
| NetPPEPurchaseAndSale | 0.00 | 35.00K | ||
| SaleOfPPE | 0.00 | 35.00K | ||
| PurchaseOfPPE | 0.00 | |||
| OperatingCashFlow | -7.17M | -7.33M | -6.21M | -6.49M |
| CashFlowFromContinuingOperatingActivities | -7.17M | -7.33M | -6.21M | -6.49M |
| ChangeInWorkingCapital | 152.00K | 526.00K | -1.06M | 485.00K |
| ChangeInOtherWorkingCapital | -259.48K | |||
| ChangeInOtherCurrentLiabilities | -28.00K | -43.00K | -46.00K | -38.00K |
| ChangeInPayablesAndAccruedExpense | -545.00K | 495.00K | -15.00K | 760.00K |
| ChangeInAccruedExpense | -185.00K | 176.00K | 44.00K | 631.00K |
| ChangeInPayable | -360.00K | 319.00K | -59.00K | 129.00K |
| ChangeInAccountPayable | -360.00K | 319.00K | -59.00K | 129.00K |
| ChangeInPrepaidAssets | 552.00K | -23.00K | -775.00K | -208.00K |
| ChangeInReceivables | 173.00K | 97.00K | -224.00K | -29.00K |
| OtherNonCashItems | 129.00K | 380.00K | 313.00K | 752.00K |
| StockBasedCompensation | 3.68M | 4.42M | 4.42M | 6.00M |
| AmortizationOfSecurities | -143.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 36.00K | 37.00K | 46.00K | 42.00K |
| DepreciationAndAmortization | 36.00K | 37.00K | 46.00K | 42.00K |
| Depreciation | 36.00K | 37.00K | 46.00K | 42.00K |
| OperatingGainsLosses | -6.00K | |||
| GainLossOnSaleOfPPE | 0.00 | -6.00K | ||
| GainLossOnSaleOfBusiness | 259.48K | |||
| NetIncomeFromContinuingOperations | -11.03M | -12.70M | -9.93M | -13.77M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ANIX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|